Nutraceuticals in rodent models as potential treatments for human Inflammatory Bowel Disease

Pharmacol Res. 2018 Jun:132:99-107. doi: 10.1016/j.phrs.2018.04.015. Epub 2018 Apr 20.

Abstract

Inflammatory Bowel Disease (IBD) is characterized by chronic inflammation of all or part of the digestive tract. Nutraceuticals include bioactive compounds such as polyphenols with anti-inflammatory activities, thus these products have the potential to treat chronic inflammatory diseases. We have emphasized the role of nutraceuticals in ameliorating the symptoms of IBD in rodent models of human IBD through modulation of key pathogenic mechanisms including dysbiosis, oxidative stress, increased inflammatory cytokines, immune system dysregulation, and inflammatory cell signaling pathways. Nutraceuticals have an important role in IBD patients as a preventive approach to extend remission phases and as a therapeutic intervention to suppress active IBD. Further clinical trials on nutraceuticals with positive results in rodent models are warranted.

Keywords: Cytokines; Gut microbiota; Inflammation; Inflammatory bowel disease; Polyphenols.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use
  • Dietary Supplements*
  • Disease Models, Animal
  • Gastrointestinal Microbiome
  • Humans
  • Inflammatory Bowel Diseases / diet therapy*
  • Inflammatory Bowel Diseases / drug therapy
  • Inflammatory Bowel Diseases / immunology
  • Inflammatory Bowel Diseases / metabolism
  • Rodentia
  • Signal Transduction

Substances

  • Anti-Inflammatory Agents